Tirzepatide CV Approval: The Overlooked 0.92 Hazard Ratio
On 28 August 2026, Eli Lilly announced that the US Food and Drug Administration had approved Mounjaro, the brand name for tirzepatide, to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them.
The approval rests on a trial in which the compound was tested against another active medicine and produced a hazard ratio of 0.92, upper confidence bound 1.01.
That trial met its non-inferiority test. It did not meet its superiority test.
A framing note. This is an approved medicine and a study of patients. Peptra Labs supplies Tirzepatide as a reference material for laboratory research, and nothing below is guidance about human use, about prescribing, or about any medical decision.
What the label now covers
The company reports that the new indication is for lowering the risk of major adverse cardiovascular events, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, in adults with type 2 diabetes at high risk for those events.
That sits on top of the existing indication as an adjunct to diet and exercise for glycaemic control in adults and in children aged 10 and over.
Lilly also states that this is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in this population. That claim is about the receptor combination, not about magnitude.
The trial behind the tirzepatide indication
SURPASS-CVOT was published in the New England Journal of Medicine on 18 December 2025, with Nicholls and Pavo as first authors. The design details below come from that paper rather than from the announcement.
It was a randomised, double-blind, active-comparator-controlled non-inferiority trial run at 640 sites in 30 countries. Participants were aged 40 or over, had type 2 diabetes and established atherosclerotic cardiovascular disease, an HbA1c between 7 and 10.5 percent, and a body mass index of 25 or above. They were assigned 1:1 to a weekly blinded subcutaneous injection of either tirzepatide up to 15 mg or dulaglutide 1.5 mg.
13,299 patients were randomised and 134 were later excluded, leaving 6,586 and 6,579 patients in the two arms. The authors report a mean age of 64.1 years, 29.0 percent women, mean body mass index 32.6, mean HbA1c 8.4 percent, and mean diabetes duration 14.7 years.
The comparator is the part worth pausing on. Dulaglutide is not a placebo. It is a GLP-1 receptor agonist with an established cardiovascular benefit of its own, which means the trial asked whether one active treatment beats another active treatment, not whether it beats nothing.
The numbers, and the rule written in advance
| SURPASS-CVOT primary endpoint | Result |
|---|---|
| Events, tirzepatide arm | 801 of 6,586, 12.2 percent |
| Events, dulaglutide arm | 862 of 6,579, 13.1 percent |
| Hazard ratio | 0.92 |
| Confidence interval | 95.3 percent CI, 0.83 to 1.01 |
| Non-inferiority margin, prespecified | upper limit below 1.05 |
| Superiority rule, prespecified | upper limit below 1.00 |
| P for non-inferiority | 0.003 |
| P for superiority | 0.09 |
The authors set both thresholds before the trial ran. An upper confidence bound under 1.05 would establish non-inferiority. An upper bound under 1.00 would establish superiority.
The observed upper bound was 1.01.
So the result cleared the first threshold comfortably and missed the second by a hundredth. The conclusion in the paper states that tirzepatide was non-inferior to dulaglutide for the composite of cardiovascular death, myocardial infarction and stroke, and stops there.
Why the distinction is not pedantry
An 8 percent lower event rate is a real number and it is the one the company quoted. It is also a point estimate whose interval still contains the possibility of no difference at all.
Prespecified thresholds exist precisely so that a result cannot be reinterpreted after the fact. When a protocol writes down in advance that superiority requires an upper bound below 1.00, and the upper bound lands at 1.01, the accurate report is that superiority was not demonstrated. That is what the paper says.
The trial did what it was designed to do. A compound that matches an agent with proven cardiovascular benefit, while also delivering larger effects on glycaemia and body weight, is a meaningful result on its own terms. It is simply a different result from the one implied by a headline about cutting heart attack risk.
The specialist literature noticed some time ago. The Journal of the American College of Cardiology published an editorial on 2 June 2026 titled “On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT”, and Heart Failure Reviews carried a piece in April 2026 titled “Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie”. Neither has a public abstract, so we are not characterising what they argue, but the titles indicate this reading is not ours alone.
What the head-to-head design bought
Testing against an active comparator is harder and more informative than testing against placebo, and the trade was explicit.
A placebo-controlled cardiovascular outcomes trial in this population is close to unrunnable now, because withholding an agent with known benefit from high-risk patients for four and a half years is difficult to justify. Choosing dulaglutide solved that problem and imposed the cost that the effect size left available to detect became small.
The same trial has already produced a prespecified exploratory analysis of major kidney events, published in Lancet Diabetes and Endocrinology in July 2026 by Zoungas, D’Alessio and colleagues. Datasets of this size keep yielding for years after the primary readout, which is one reason the primary number deserves to be stated precisely at the start.
Where it sits in a month of reading
This is the fourth time in August that a large dataset has separated a compound’s metabolic effects from its hard outcomes.
We covered a matched cohort where hard liver outcomes came out level despite one arm losing more body mass index. We covered a heart failure trial read by sex, and a SURMOUNT post hoc analysis of composite endpoints where the choice of endpoint changed the picture. Yesterday we reported a comparison in which surgery removed far more liver fat than a GLP-1 agonist did and produced no significant difference in relative liver stiffness reduction.
Here the pattern appears in the cleanest available setting. Tirzepatide produces larger reductions in HbA1c and body weight than dulaglutide does, and the composite cardiovascular endpoint did not separate. Whatever drives macrovascular events in this population is evidently not a simple function of how much glycaemic control or body weight an agent delivers.
What this means for the catalogue
Laboratories buying reference material prescribe nothing, and the transferable content here is about how a trial result gets worded.
The distance between “non-inferior with a hazard ratio of 0.92” and “reduces cardiovascular risk” is the distance between a statistical finding and a regulatory label, and both statements are defensible in their own register. Anyone reading published work on incretin compounds will meet that gap repeatedly, and the fix is always the same: find the prespecified threshold, then find the confidence bound.
Retatrutide, the triple agonist, has no cardiovascular outcomes trial reported at all, so no equivalent statement exists for it in either register. The Cardiovascular Diabetology review published on 26 August 2026 describes the compound as awaiting exactly this kind of data.
For laboratories, our European research buyer guide covers procurement and documentation, everything is supplied on a research use only basis, and our ranking of the most-studied research peptides tracks the published record rather than the label.
References
- Eli Lilly and Company. FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. 28 August 2026
- Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine, 18 December 2025, 393(24):2409-2420. doi 10.1056/NEJMoa2505928. SURPASS-CVOT, NCT04255433
- Kaul S. On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT. Journal of the American College of Cardiology, 2 June 2026, 87(21):3029-3031
- Zoungas S, D’Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes and Endocrinology, July 2026, 14(7):544-557
- Koca N, Uyar S, Sahinturk Y, et al. Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception. Cardiovascular Diabetology, 26 August 2026
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
